Product Images Memantine Hydrochloride

This is a medication label for a product called HehaNTINE HYDROCHLORTDE. It contains 16 mg of an unknown substance and comes in a bottle with 90 tablets. The recommended storage temperature is 6870 7 degrees Celsius. Not all the characters are readable due to errors.*

This is a graph titled "Time course of the change from baseline in ADCS-ADL score for patients completing 28 weeks of treatment". The x-axis is labeled with "Weeks of Treatment" and ranges from 0 to 28. The y-axis is labeled with "ADCS-ADL score" and ranges from -8 to 20. The graph shows two lines: a declining line representing "Clinical Decline" and a rising line representing "Clinical Improvement". The top of the graph has some text, including "Placebo" and "Memantine Hydrochloride". This may be a study evaluating the effects of these treatments on patients.*

This is a graph showing the cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. The medications being tested are Placebo and Memantine Hydrochloride. There is no further information available.*

This is a graph displaying the time course of change from baseline in SIB score for patients who completed 28 weeks of treatment. There are two lines shown, one for the placebo and another for the memantine hydrochloride treatment. The graph also displays the mean change from baseline for each treatment. There is no further information available from this text.*

The text describes a graph showing the cumulative percentage of patients undergoing treatment with Placebo and Memantine Hydrochloride. The patients completed 28 weeks of double-blind treatment, and the graph displays the specified changes from baseline in SIB scores.*

The text is describing a figure showing the time course of the change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment with either placebo/donepezil or memantine hydrochloride/donepezil. The figure shows that the memantine hydrochloride/donepezil group had a clinical improvement in ADCS-ADL score, whereas the placebo/donepezil group had a decline. A mean change from baseline is also mentioned.*

This text is a graph and does not provide a useful description.*

This text describes a figure showing the time course of the change from baseline in SIB score for patients completing 24 weeks of treatment with either a placebo/donepezil or memantine hydrochloride/donepezil. The figure shows the mean (+SEM) change from baseline over the duration of the treatment.*

The figure shows the cumulative percentage of patients who completed 24 weeks of double-blind treatment with specified changes from baseline in SIB scores. Two medications are compared: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. No further information is available.*